GlassScriptPhysician profile
Lisa Webster
NPI 1467142356
$869.73
in general payments reported to CMS, 2019-2025
13 companies · $465 in 2025
The $465 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $30.29 · 2024: $375 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $869.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $181.49 | 2024-2025 | Repatha, Otezla, Otezla |
| Dexcom, INC. | $148.51 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $119.06 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astrazeneca Pharmaceuticals LP | $110.72 | 2024-2025 | Airsupra, Farxiga |
| Exact Sciences Corporation | $71.45 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $50.70 | 2024-2025 | Shingrix, Bexsero, Pediarix |
| Pfizer INC. | $39.37 | 2024-2025 | |
| Abbvie INC. | $39.08 | 2023-2025 | |
| Lilly USA, LLC | $29.79 | 2025 | Mounjaro |
| Novo Nordisk INC | $24.13 | 2025 | Wegovy |
| Insulet Corporation | $23.28 | 2025 | Omnipod |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.68 | 2025 | Caplyta |
| Csl Behring | $14.47 | 2023 | Idelvion, Afstyla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Webster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.